A retrospective analysis of more than 7k patients from the ACCORD trial suggests intensive blood pressure and intensive blood glucose control could reduce the risk of cardiovascular autonomic neuropathy in diabetics.
A resident from Penn State Hershey Medical Center offers his perspective on the potential of the SGLT2 inhibitor class to transform the treatment of diabetes and cardiovascular disease among patients with diabetes.
Data from an analysis of more than 25k women by a team from Brigham and Women's Hospital and Harvard Medical School suggests greater adherence to a Mediterranean diet was linked to a lower risk of developing diabetes.
In this 3-part feature series, an endocrinologist, a cardiologist, and an internist tackle the topic of who should be in charge of treating patients with diabetes and whether the creation of a cardiometabolic specialty is a worthwhile endeavor.
TRANSLATE-HF is a collaborative effort between the AHA and AstraZeneca with the goal of increasing and optimizing SGLT2 inhibitor use in US patients. Hear further insight lead author from the first of 6 TRANSLATE-HF studies, which was presented at AHA 2020.
Data from the phase 3 SOLOIST-WHF and SCORED trials suggest sotagliflozin was associated with significant reductions in death from CVD in patients with worsening heart failure and significant reductions in blood glucose levels among patients with moderate to severe kidney impairment.